Project Grant R44CA287634
Award Date
9/20/24
Completion Date
8/31/26
Dollars Obligated
$995K
Federal Agency
National Cancer Institute
Awardee
Cytoagents Inc. (CCEZCKNKL9M4)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,220,394 to the Sloan-Kettering Institute for Cancer Research to conduct comprehensive molecular and clinical characterization of acute and chronic neurotoxicity following CAR-T cell therapy. The research aims to investigate the pathogenesis of acute immune effector cell-associated neurotoxicity syndrome (ICANS) and assess neurocognitive function and neuroimaging outcomes in...
This $1,013,623 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to March Biosciences Inc. aims to develop dual-targeting chimeric antigen receptor (CAR) T-cell therapies for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The grant will fund the development of CD5/CD7.CAR-T cells derived from haploidentical, CD45RA-depleted donor T-cells (RAD-T) to target malignant T-cells with varying antigen expression....
This $1,477,396 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop an innovative approach to enhance the efficacy and durability of CD19-targeted CAR T-cell therapy for B-cell non-Hodgkin's lymphoma (B-NHL). The key elements include: Selecting cytomegalovirus (CMV)-specific T cells for modification with a CD19-targeting CAR, and then infusing the resulting bi-specific CMV-CD19 CAR T cells into patients. Inducing expansion of the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award of $513,859, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to develop a novel adoptive cellular therapy platform using hematopoietic stem cells (HSCs) engineered with chimeric antigen receptor (CAR) technology. The goal is to generate a continuously renewing population of CAR-expressing natural killer (NK) cells that can provide long-term, safe, and efficacious anti-cancer immunity. The research aims to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $665,000 to support the development and clinical testing of MT-601, a novel multi-tumor associated antigen (MTAA)-specific T-cell therapy for the treatment of non-Hodgkin lymphoma (NHL). The key objectives of this project are to manufacture the MT-601 product and conduct a Phase 1 clinical trial evaluating its safety and efficacy in NHL patients who have relapsed after prior CD19...
This federal Project Grant award for $1,108,391.72, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at The Leland Stanford Junior University to define the optimal characteristics of chimeric antigen receptor (CAR) T cells for the treatment of large B-cell lymphoma (LBCL). The key research goals are: (1) to identify the most therapeutically relevant CAR T cell subsets in LBCL patients, and (2) to overcome immune suppression by CAR T...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Luminary Therapeutics, Inc., a self-certified small disadvantaged business, to develop an innovative chimeric antigen receptor (CAR) T-cell therapy targeting epithelial ovarian carcinoma. The $798,512 award, with a project period from September 2024 to August 2025, supports the development of an "armored split CAR" T-cell product that combines two CAR molecules...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $748,337 to Pyrojas Inc. to develop "Pyrotimer CAR-T cells" - an innovative approach that aims to inhibit the TGF-beta pathway and enhance the persistence and cytotoxicity of CAR-T cell therapies within the immunosuppressive tumor microenvironment. The key objectives are to: 1) Decipher the influence of TGF-beta on Pyrotimer CAR-T cells, 2) Profile cytokine...